by Dan Roberts June 2013 INTRODUCTION This is a summary of reports about significant research and development in the field of macular degeneration and related diseases presented since June 2012 and May 2013. I will briefly describe the conclusions of 77 studies that have been presented in the areas of therapy, prevention, technology, nutrition and [Read More]
Tag: Avastin
Antiangiogenic Drugs Are Stopping Neovascularization in Wet Macular Degeneration
(Updated 3/12/22) A substance in the body called Vascular Endothelial Growth Factor (VEGF) is responsible for the growth of new blood vessels. It promotes this growth by stimulating the endothelial cells, which form the walls of the vessels and transport nutrients and oxygen to the tissues. Evidence shows that when the retinal pigment epithelial (RPE) [Read More]
Summary of Research and Developments in Macular Degeneration, 2011-2012
by Dan Roberts June 2012 Introduction Here is MD Support’s summary of the the past twelve months of significant research and development in the field of macular degeneration. We begin with the field that has been making the most news: pharmacology. _______________________________ PHARMACOLOGY SEP: Infection Risk From Repackaged Avastin The big pharmaceutical news of the [Read More]
Summary of Research and Developments in Macular Degeneration, 2010-2011
by Dan Roberts June 19, 2011 Introduction Since 2006, I have done my best to condense the high points of the previous year’s macular degeneration research into a single report that is concise and understandable for the layperson. I do so, because I understand first hand how important it is to be aware of everything [Read More]
Spikes in IOP May Result From Particulate Matter in Avastin
by Dan Roberts In a presentation to Hawaiian Eye 2010, Malik Y. Kahook, MD, said that Avastin (bevacizumab) stored for long periods of time shows evidence of increased large particulate matter. This debris can block the eye’s trabecular network and lead to increased intraocular pressure (IOP) in patients being treated with the drug for wet [Read More]